PBYI

Puma Biotechnology is a biopharmaceutical company focused on the development and commercialization of innovative products to enhance cancer care. The company markets NERLYNX (neratinib), an oral kinase inhibitor approved for the extended adjuvant treatment of early-stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy. Puma also has a pipeline of drug candidates in clinical development for various oncology indications. The company was founded in 2010 and is headquartered in Los Angeles, California.